Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02065193
Other study ID # China SCORE study
Secondary ID
Status Recruiting
Phase N/A
First received February 12, 2014
Last updated February 14, 2014
Start date April 2013

Study information

Verified date February 2014
Source University of Cambridge
Contact Xiang Sun, PhD
Email xs227@medschl.cam.ac.uk
Is FDA regulated No
Health authority China :China Disabled Persons' Federation
Study type Observational

Clinical Trial Summary

The China SCORE study is a prevalence study of Autism Spectrum Conditions (ASC) in 14 regions in mainland China. It will include the following steps:

1. Large population-based screening This study will be conducted in urban areas but not rural areas across mainland China. One city of each region will participate, and in total there will be 14 cities for screening. Within each city, a number of 40 to 60 ordinary primary schools will be randomly selected from the defined region. All the students who are in 1st to 4th grade will asked to participate in order to form a sample of approximately 20,000 students.

Screening questionnaires The screening pack includes the Chinese CAST, the AQ-Child, the AQ-Adult short version (10 items), and risk factors questionnaire. An information sheet and consent form will be included in the pack as well.

2. Further assessments We expect approximately 5% on the CAST will score positive in ordinary school population. Thus, for a 20,000 sample, we would expect 900 positives (90% response rate). All the screen-positives and a random selected 5% from borderline group will be invited for clinical assessment. The diagnosis of clinical assessment will be divided into three categories: definite ASC, suspected ASC, and non-ASC. Then all the children with clinical assessment results as definite ASC and suspected ASC and a randomly selected 10-20 non-ASC will be invited for research diagnostic assessment using the ADOS and ADI-R, as well as RPM as IQ test. After that, the consensus diagnosis between ADOS/ADI-R assessment and the clinical diagnosis will be the final diagnosis.

3. Case identification in special schools All the children in special schools or training institutes in study region will be asked to fill in the screening pack. The children who do not attend any ordinary or special schools will be identified according to their residential ID in the studied regions. All screen-positives in special education will be assessed using the ADOS and ADI-R. Then those who met the criteria of ASC on ADOS or/and ADI-R will be assessed by psychiatrists and the clinical diagnosis will be the final diagnosis.

If we combine the prevalence of ordinary schools and special schools together, we will get an estimate of the prevalence of ASC in school-population in China. If we combine all the cases identified from schools and from residential records, we will generate an estimate of the prevalence of ASC in the general population in mainland China.


Recruitment information / eligibility

Status Recruiting
Enrollment 280000
Est. completion date
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender Both
Age group 6 Years to 11 Years
Eligibility Inclusion Criteria:

- All children who are in study region will be recruited for this study.

- All children aged 6-11 years old.

Exclusion Criteria:

- Children who are not in the study region.

- Children who are not found from ordinary schools, private training centres, public special schools and community household with the help of local residence records will not be included for this study.

Study Design

Observational Model: Ecologic or Community, Time Perspective: Prospective


Related Conditions & MeSH terms

  • Autism Spectrum Conditions/Disorders
  • Disease

Intervention

Behavioral:
ADOS/ADI-R/Clinical assessment


Locations

Country Name City State
China Beijing CDPF Beijing
China Liaoning CDPF Benxi Liaoning
China Shanxi CDPF Changzhi Shanxi
China Fujian CDPF Fuzhou Fujian
China Guangdong CDPF Guangzhou
China Zhejiang CDPF Hangzhou
China Hengyang CDPF Hengyang Hunan
China Heilongjiang CDPF Jiamusi Heilongjiang
China Jilin Mingzhi Centre Jilin Jilin
China Luoyang CDPF Luoyang Henan
China Shenzhen CDPF Shenzhen Guangdong
China Hubei CDPF Wuhan
China Shanxi CDPF Xian Shanxi
China Jiangsu CDPF Yangzhou

Sponsors (3)

Lead Sponsor Collaborator
University of Cambridge China Disabled Persons Federation, Chinese University of Hong Kong

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Three-staged consensus diagnosis The prevalence of Autism Spectrum Conditions will be measured using screening and diagnostic instruments including the Childhood Autism Spectrum Test , the Autism Diagnostic Observation Schedule, the Autism Diagnostic Interview-Revised, and Clinical diagnosis. The assessments will be finished in one year. No